SG187744A1 - Treatment of mitochondrial diseases with naphthoquinones - Google Patents

Info

Publication number

SG187744A1

SG187744A1 SG2013009212A SG2013009212A SG187744A1 SG 187744 A1 SG187744 A1 SG 187744A1 SG 2013009212 A SG2013009212 A SG 2013009212A SG 2013009212 A SG2013009212 A SG 2013009212A SG 187744 A1 SG187744 A1 SG 187744A1

Authority

SG

Singapore

Prior art keywords

alkyl

levels

dione

hydrogen

compounds

Prior art date

2010-08-06

Links

• Espacenet
• Global Dossier
• Discuss

• 208000012268 mitochondrial disease Diseases 0.000 title claims abstract description 77
• 238000011282 treatment Methods 0.000 title description 26
• 229930192627 Naphthoquinone Natural products 0.000 title description 5
• 150000002791 naphthoquinones Chemical class 0.000 title description 5
• 239000000090 biomarker Substances 0.000 claims abstract description 187
• 150000001875 compounds Chemical class 0.000 claims abstract description 160
• 238000000034 method Methods 0.000 claims abstract description 90
• 208000024891 symptom Diseases 0.000 claims abstract description 51
• 208000024412 Friedreich ataxia Diseases 0.000 claims abstract description 35
• 208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 claims abstract description 26
• 201000000639 Leber hereditary optic neuropathy Diseases 0.000 claims abstract description 26
• 206010048804 Kearns-Sayre syndrome Diseases 0.000 claims abstract description 23
• 208000001992 Autosomal Dominant Optic Atrophy Diseases 0.000 claims abstract description 21
• 206010058799 Mitochondrial encephalomyopathy Diseases 0.000 claims abstract description 19
• 201000002169 Mitochondrial myopathy Diseases 0.000 claims abstract description 19
• 208000006136 Leigh Disease Diseases 0.000 claims abstract description 16
• 208000017507 Leigh syndrome Diseases 0.000 claims abstract description 16
• 208000023692 inborn mitochondrial myopathy Diseases 0.000 claims abstract description 15
• 208000014644 Brain disease Diseases 0.000 claims abstract description 10
• 208000032274 Encephalopathy Diseases 0.000 claims abstract description 10
• 125000000217 alkyl group Chemical group 0.000 claims description 89
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 64
• 239000001257 hydrogen Substances 0.000 claims description 52
• 229910052739 hydrogen Inorganic materials 0.000 claims description 52
• 239000000203 mixture Substances 0.000 claims description 48
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 42
• ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 41
• 235000017471 coenzyme Q10 Nutrition 0.000 claims description 39
• 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 claims description 36
• 150000003839 salts Chemical class 0.000 claims description 36
• 102000018832 Cytochromes Human genes 0.000 claims description 29
• 108010052832 Cytochromes Proteins 0.000 claims description 29
• 208000035475 disorder Diseases 0.000 claims description 24
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 24
• FRASJONUBLZVQX-UHFFFAOYSA-N 1,4-naphthoquinone Chemical compound C1=CC=C2C(=O)C=CC(=O)C2=C1 FRASJONUBLZVQX-UHFFFAOYSA-N 0.000 claims description 23
• 230000002829 reductive effect Effects 0.000 claims description 23
• 239000000651 prodrug Substances 0.000 claims description 22
• 229940002612 prodrug Drugs 0.000 claims description 22
• 210000004369 blood Anatomy 0.000 claims description 21
• 239000008280 blood Substances 0.000 claims description 21
• 239000012453 solvate Substances 0.000 claims description 21
• JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 19
• XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 claims description 19
• 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 19
• 230000002490 cerebral effect Effects 0.000 claims description 17
• BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 claims description 17
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 16
• 201000009035 MERRF syndrome Diseases 0.000 claims description 16
• DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 claims description 16
• 210000002381 plasma Anatomy 0.000 claims description 15
• 230000004064 dysfunction Effects 0.000 claims description 14
• 239000002207 metabolite Substances 0.000 claims description 14
• 239000012530 fluid Substances 0.000 claims description 13
• 230000000241 respiratory effect Effects 0.000 claims description 13
• 201000009623 Myopathy Diseases 0.000 claims description 12
• LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 claims description 12
• WDJHALXBUFZDSR-UHFFFAOYSA-M acetoacetate Chemical compound CC(=O)CC([O-])=O WDJHALXBUFZDSR-UHFFFAOYSA-M 0.000 claims description 12
• 229940076788 pyruvate Drugs 0.000 claims description 12
• 230000002861 ventricular Effects 0.000 claims description 12
• HCAJQHYUCKICQH-VPENINKCSA-N 8-Oxo-7,8-dihydro-2'-deoxyguanosine Chemical compound C1=2NC(N)=NC(=O)C=2NC(=O)N1[C@H]1C[C@H](O)[C@@H](CO)O1 HCAJQHYUCKICQH-VPENINKCSA-N 0.000 claims description 11
• 208000018737 Parkinson disease Diseases 0.000 claims description 11
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 8
• 239000001569 carbon dioxide Substances 0.000 claims description 8
• 229910002092 carbon dioxide Inorganic materials 0.000 claims description 8
• 229950007002 phosphocreatine Drugs 0.000 claims description 8
• 208000016354 hearing loss disease Diseases 0.000 claims description 7
• 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 7
• KVZLHPXEUGJPAH-UHFFFAOYSA-N 2-oxidanylpropanoic acid Chemical compound CC(O)C(O)=O.CC(O)C(O)=O KVZLHPXEUGJPAH-UHFFFAOYSA-N 0.000 claims description 6
• 206010011878 Deafness Diseases 0.000 claims description 6
• 208000023105 Huntington disease Diseases 0.000 claims description 6
• 231100000888 hearing loss Toxicity 0.000 claims description 6
• 230000010370 hearing loss Effects 0.000 claims description 6
• 230000036284 oxygen consumption Effects 0.000 claims description 6
• HWKRAUXFMLQKLS-UHFFFAOYSA-N 2-oxidanylidenepropanoic acid Chemical compound CC(=O)C(O)=O.CC(=O)C(O)=O HWKRAUXFMLQKLS-UHFFFAOYSA-N 0.000 claims description 5
• 208000024827 Alzheimer disease Diseases 0.000 claims description 5
• 239000003642 reactive oxygen metabolite Substances 0.000 claims description 5
• QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 4
• 201000010384 renal tubular acidosis Diseases 0.000 claims description 4
• 208000031229 Cardiomyopathies Diseases 0.000 claims description 3
• 150000002431 hydrogen Chemical class 0.000 claims description 3
• 230000002708 enhancing effect Effects 0.000 abstract description 26
• 201000010099 disease Diseases 0.000 description 40
• 210000004027 cell Anatomy 0.000 description 38
• 230000037396 body weight Effects 0.000 description 31
• 210000002950 fibroblast Anatomy 0.000 description 20
• ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 19
• ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 18
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 16
• 230000003247 decreasing effect Effects 0.000 description 16
• 239000003814 drug Substances 0.000 description 16
• 229910052760 oxygen Inorganic materials 0.000 description 16
• 239000001301 oxygen Substances 0.000 description 16
• 230000001629 suppression Effects 0.000 description 16
• -1 Vitamin K compounds Chemical class 0.000 description 15
• 230000001684 chronic effect Effects 0.000 description 14
• 230000004065 mitochondrial dysfunction Effects 0.000 description 14
• 210000001519 tissue Anatomy 0.000 description 14
• 229940088594 vitamin Drugs 0.000 description 13
• 229930003231 vitamin Natural products 0.000 description 13
• 235000013343 vitamin Nutrition 0.000 description 13
• 239000011782 vitamin Substances 0.000 description 13
• 230000002503 metabolic effect Effects 0.000 description 12
• 230000035806 respiratory chain Effects 0.000 description 12
• ZEGDFCCYTFPECB-UHFFFAOYSA-N 2,3-dimethoxynaphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(OC)=C(OC)C(=O)C2=C1 ZEGDFCCYTFPECB-UHFFFAOYSA-N 0.000 description 11
• OBGBGHKYJAOXRR-UHFFFAOYSA-N 2-methoxy-1,4-naphthoquinone Chemical compound C1=CC=C2C(=O)C(OC)=CC(=O)C2=C1 OBGBGHKYJAOXRR-UHFFFAOYSA-N 0.000 description 11
• 206010010904 Convulsion Diseases 0.000 description 11
• 230000001154 acute effect Effects 0.000 description 11
• 238000009472 formulation Methods 0.000 description 11
• 239000000243 solution Substances 0.000 description 11
• 238000012360 testing method Methods 0.000 description 11
• 208000021642 Muscular disease Diseases 0.000 description 10
• 208000006011 Stroke Diseases 0.000 description 10
• 230000000694 effects Effects 0.000 description 10
• 230000001965 increasing effect Effects 0.000 description 10
• 210000003470 mitochondria Anatomy 0.000 description 10
• 238000010606 normalization Methods 0.000 description 10
• 150000003722 vitamin derivatives Chemical class 0.000 description 10
• BXRGMKVTCTWHRD-UHFFFAOYSA-N 2-butyl-3-methylnaphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(CCCC)=C(C)C(=O)C2=C1 BXRGMKVTCTWHRD-UHFFFAOYSA-N 0.000 description 9
• DIIHNBLSXDGYNT-UHFFFAOYSA-N 2-hexyl-3-methylnaphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(CCCCCC)=C(C)C(=O)C2=C1 DIIHNBLSXDGYNT-UHFFFAOYSA-N 0.000 description 9
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
• BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 9
• 230000009286 beneficial effect Effects 0.000 description 9
• 230000007812 deficiency Effects 0.000 description 9
• 230000006872 improvement Effects 0.000 description 9
• 239000002609 medium Substances 0.000 description 9
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 9
• 239000000523 sample Substances 0.000 description 9
• 238000002560 therapeutic procedure Methods 0.000 description 9
• 239000003963 antioxidant agent Substances 0.000 description 8
• 235000006708 antioxidants Nutrition 0.000 description 8
• 230000008901 benefit Effects 0.000 description 8
• 239000000835 fiber Substances 0.000 description 8
• 235000013305 food Nutrition 0.000 description 8
• RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 8
• 208000006443 lactic acidosis Diseases 0.000 description 8
• 230000035772 mutation Effects 0.000 description 8
• 229950006238 nadide Drugs 0.000 description 8
• 239000003981 vehicle Substances 0.000 description 8
• 206010003591 Ataxia Diseases 0.000 description 7
• VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 7
• 238000003556 assay Methods 0.000 description 7
• 210000004556 brain Anatomy 0.000 description 7
• 229940079593 drug Drugs 0.000 description 7
• 230000002500 effect on skin Effects 0.000 description 7
• 206010016256 fatigue Diseases 0.000 description 7
• 239000002502 liposome Substances 0.000 description 7
• 239000007788 liquid Substances 0.000 description 7
• ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 6
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
• 229940110767 coenzyme Q10 Drugs 0.000 description 6
• 230000002950 deficient Effects 0.000 description 6
• 230000036541 health Effects 0.000 description 6
• 238000000338 in vitro Methods 0.000 description 6
• 238000001727 in vivo Methods 0.000 description 6
• JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
• 238000005259 measurement Methods 0.000 description 6
• 210000003205 muscle Anatomy 0.000 description 6
• 230000001575 pathological effect Effects 0.000 description 6
• 238000002360 preparation method Methods 0.000 description 6
• 238000012216 screening Methods 0.000 description 6
• 239000002904 solvent Substances 0.000 description 6
• 239000000126 substance Substances 0.000 description 6
• 229940124597 therapeutic agent Drugs 0.000 description 6
• LGFDNUSAWCHVJN-UHFFFAOYSA-N 2,3-dimethyl-1,4-naphthoquinone Chemical compound C1=CC=C2C(=O)C(C)=C(C)C(=O)C2=C1 LGFDNUSAWCHVJN-UHFFFAOYSA-N 0.000 description 5
• 206010011891 Deafness neurosensory Diseases 0.000 description 5
• KJQFBVYMGADDTQ-CVSPRKDYSA-N L-buthionine-(S,R)-sulfoximine Chemical compound CCCCS(=N)(=O)CC[C@H](N)C(O)=O KJQFBVYMGADDTQ-CVSPRKDYSA-N 0.000 description 5
• 206010050029 Mitochondrial cytopathy Diseases 0.000 description 5
• 208000009966 Sensorineural Hearing Loss Diseases 0.000 description 5
• 239000013543 active substance Substances 0.000 description 5
• 230000002411 adverse Effects 0.000 description 5
• 235000015872 dietary supplement Nutrition 0.000 description 5
• 208000014674 injury Diseases 0.000 description 5
• 239000000463 material Substances 0.000 description 5
• 208000015122 neurodegenerative disease Diseases 0.000 description 5
• 210000000056 organ Anatomy 0.000 description 5
• 230000036542 oxidative stress Effects 0.000 description 5
• SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 5
• 239000006187 pill Substances 0.000 description 5
• 230000002265 prevention Effects 0.000 description 5
• 208000023573 sensorineural hearing loss disease Diseases 0.000 description 5
• 239000000725 suspension Substances 0.000 description 5
• 208000011580 syndromic disease Diseases 0.000 description 5
• 238000003786 synthesis reaction Methods 0.000 description 5
• 239000003826 tablet Substances 0.000 description 5
• WHBMMWSBFZVSSR-UHFFFAOYSA-M 3-hydroxybutyrate Chemical compound CC(O)CC([O-])=O WHBMMWSBFZVSSR-UHFFFAOYSA-M 0.000 description 4
• 208000010354 Coenzyme Q10 deficiency Diseases 0.000 description 4
• 206010012289 Dementia Diseases 0.000 description 4
• 206010021118 Hypotonia Diseases 0.000 description 4
• 208000007379 Muscle Hypotonia Diseases 0.000 description 4
• 208000036572 Myoclonic epilepsy Diseases 0.000 description 4
• 229930003448 Vitamin K Natural products 0.000 description 4
• 230000032683 aging Effects 0.000 description 4
• 229940024606 amino acid Drugs 0.000 description 4
• 150000001413 amino acids Chemical class 0.000 description 4
• 239000002775 capsule Substances 0.000 description 4
• 230000000747 cardiac effect Effects 0.000 description 4
• 230000008859 change Effects 0.000 description 4
• 239000003795 chemical substances by application Substances 0.000 description 4
• 230000006735 deficit Effects 0.000 description 4
• 235000005911 diet Nutrition 0.000 description 4
• 239000003937 drug carrier Substances 0.000 description 4
• 239000000839 emulsion Substances 0.000 description 4
• 229960003180 glutathione Drugs 0.000 description 4
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
• 238000004519 manufacturing process Methods 0.000 description 4
• 230000002438 mitochondrial effect Effects 0.000 description 4
• 230000036961 partial effect Effects 0.000 description 4
• 230000037081 physical activity Effects 0.000 description 4
• 230000000750 progressive effect Effects 0.000 description 4
• 230000002035 prolonged effect Effects 0.000 description 4
• 230000009467 reduction Effects 0.000 description 4
• 238000011160 research Methods 0.000 description 4
• 231100000879 sensorineural hearing loss Toxicity 0.000 description 4
• 230000035939 shock Effects 0.000 description 4
• 241000894007 species Species 0.000 description 4
• 230000001225 therapeutic effect Effects 0.000 description 4
• 230000008733 trauma Effects 0.000 description 4
• 230000004102 tricarboxylic acid cycle Effects 0.000 description 4
• 235000019168 vitamin K Nutrition 0.000 description 4
• 239000011712 vitamin K Substances 0.000 description 4
• 229940046010 vitamin k Drugs 0.000 description 4
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
• GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 4
• QWIBLPIAYFAQQQ-UHFFFAOYSA-N 2-ethyl-3-methylnaphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(CC)=C(C)C(=O)C2=C1 QWIBLPIAYFAQQQ-UHFFFAOYSA-N 0.000 description 3
• 206010003805 Autism Diseases 0.000 description 3
• 208000020706 Autistic disease Diseases 0.000 description 3
• 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 3
• 201000003883 Cystic fibrosis Diseases 0.000 description 3
• 206010014561 Emphysema Diseases 0.000 description 3
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
• 241000282412 Homo Species 0.000 description 3
• 208000019693 Lung disease Diseases 0.000 description 3
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
• 238000004497 NIR spectroscopy Methods 0.000 description 3
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
• OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• 208000004756 Respiratory Insufficiency Diseases 0.000 description 3
• 208000007014 Retinitis pigmentosa Diseases 0.000 description 3
• 208000020221 Short stature Diseases 0.000 description 3
• 102000046669 Surf-1 Human genes 0.000 description 3
• 108060007963 Surf-1 Proteins 0.000 description 3
• 230000002159 abnormal effect Effects 0.000 description 3
• 230000005856 abnormality Effects 0.000 description 3
• 239000002253 acid Substances 0.000 description 3
• 239000002671 adjuvant Substances 0.000 description 3
• 238000003915 air pollution Methods 0.000 description 3
• 230000003078 antioxidant effect Effects 0.000 description 3
• 239000002585 base Substances 0.000 description 3
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
• 230000015572 biosynthetic process Effects 0.000 description 3
• 239000000872 buffer Substances 0.000 description 3
• 125000004432 carbon atom Chemical group C* 0.000 description 3
• 238000004113 cell culture Methods 0.000 description 3
• 230000030833 cell death Effects 0.000 description 3
• 210000003169 central nervous system Anatomy 0.000 description 3
• 230000004087 circulation Effects 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
• 239000002552 dosage form Substances 0.000 description 3
• 230000002255 enzymatic effect Effects 0.000 description 3
• 238000002474 experimental method Methods 0.000 description 3
• JGPMMRGNQUBGND-UHFFFAOYSA-N idebenone Chemical compound COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O JGPMMRGNQUBGND-UHFFFAOYSA-N 0.000 description 3
• 229960004135 idebenone Drugs 0.000 description 3
• 239000003701 inert diluent Substances 0.000 description 3
• 208000028867 ischemia Diseases 0.000 description 3
• 239000004310 lactic acid Substances 0.000 description 3
• 235000014655 lactic acid Nutrition 0.000 description 3
• 150000002632 lipids Chemical class 0.000 description 3
• 210000004072 lung Anatomy 0.000 description 3
• 201000005202 lung cancer Diseases 0.000 description 3
• 208000020816 lung neoplasm Diseases 0.000 description 3
• 239000011159 matrix material Substances 0.000 description 3
• 239000012528 membrane Substances 0.000 description 3
• 210000004379 membrane Anatomy 0.000 description 3
• GVZFUVXPTPGOQT-UHFFFAOYSA-M mitoq Chemical compound CS([O-])(=O)=O.O=C1C(OC)=C(OC)C(=O)C(CCCCCCCCCC[P+](C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1C GVZFUVXPTPGOQT-UHFFFAOYSA-M 0.000 description 3
• 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 3
• 230000004770 neurodegeneration Effects 0.000 description 3
• 231100000252 nontoxic Toxicity 0.000 description 3
• 230000003000 nontoxic effect Effects 0.000 description 3
• 230000002853 ongoing effect Effects 0.000 description 3
• 206010030875 ophthalmoplegia Diseases 0.000 description 3
• 230000010627 oxidative phosphorylation Effects 0.000 description 3
• 239000008194 pharmaceutical composition Substances 0.000 description 3
• 239000000843 powder Substances 0.000 description 3
• 230000002028 premature Effects 0.000 description 3
• 239000000047 product Substances 0.000 description 3
• 102000004169 proteins and genes Human genes 0.000 description 3
• 108090000623 proteins and genes Proteins 0.000 description 3
• 201000004193 respiratory failure Diseases 0.000 description 3
• 230000004044 response Effects 0.000 description 3
• 230000000284 resting effect Effects 0.000 description 3
• 210000002027 skeletal muscle Anatomy 0.000 description 3
• 238000001356 surgical procedure Methods 0.000 description 3
• 239000000375 suspending agent Substances 0.000 description 3
• 230000002792 vascular Effects 0.000 description 3
• 230000035899 viability Effects 0.000 description 3
• 150000003721 vitamin K derivatives Chemical class 0.000 description 3
• XOQNYHSBHIIJMQ-UHFFFAOYSA-N 2',3'-dihydro-phytomenadione Chemical compound C1=CC=C2C(=O)C(CCC(C)CCCC(C)CCCC(C)CCCC(C)C)=C(C)C(=O)C2=C1 XOQNYHSBHIIJMQ-UHFFFAOYSA-N 0.000 description 2
• LWWOWQZGAGVVEU-UHFFFAOYSA-N 2,3,6-trimethylnaphthalene-1,4-dione Chemical compound CC1=CC=C2C(=O)C(C)=C(C)C(=O)C2=C1 LWWOWQZGAGVVEU-UHFFFAOYSA-N 0.000 description 2
• NMCXQXPAQRKPIH-UHFFFAOYSA-N 2-(3-hydroxy-3,7-dimethyloctyl)-6,7-dimethoxy-3-methylnaphthalene-1,4-dione Chemical compound O=C1C(C)=C(CCC(C)(O)CCCC(C)C)C(=O)C2=C1C=C(OC)C(OC)=C2 NMCXQXPAQRKPIH-UHFFFAOYSA-N 0.000 description 2
• JZCYOZPRLAGWSS-UHFFFAOYSA-N 2-decyl-3-methylnaphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(CCCCCCCCCC)=C(C)C(=O)C2=C1 JZCYOZPRLAGWSS-UHFFFAOYSA-N 0.000 description 2
• QDUAOKYKHMKPTA-UHFFFAOYSA-N 2-methyl-3-nonylnaphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(CCCCCCCCC)=C(C)C(=O)C2=C1 QDUAOKYKHMKPTA-UHFFFAOYSA-N 0.000 description 2
• GIQISUKKXZTPJV-UHFFFAOYSA-N 2-methyl-3-propylnaphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(CCC)=C(C)C(=O)C2=C1 GIQISUKKXZTPJV-UHFFFAOYSA-N 0.000 description 2
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
• 201000004569 Blindness Diseases 0.000 description 2
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
• 206010008025 Cerebellar ataxia Diseases 0.000 description 2
• 201000000915 Chronic Progressive External Ophthalmoplegia Diseases 0.000 description 2
• 206010010356 Congenital anomaly Diseases 0.000 description 2
• 229920000858 Cyclodextrin Polymers 0.000 description 2
• 208000002155 Cytochrome-c Oxidase Deficiency Diseases 0.000 description 2
• 206010012559 Developmental delay Diseases 0.000 description 2
• 208000014094 Dystonic disease Diseases 0.000 description 2
• 108010024882 Electron Transport Complex III Proteins 0.000 description 2
• 102000015782 Electron Transport Complex III Human genes 0.000 description 2
• 102000009024 Epidermal Growth Factor Human genes 0.000 description 2
• YPZRHBJKEMOYQH-UYBVJOGSSA-N FADH2 Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1COP(O)(=O)OP(O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C(NC(=O)NC2=O)=C2NC2=C1C=C(C)C(C)=C2 YPZRHBJKEMOYQH-UYBVJOGSSA-N 0.000 description 2
• 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
• 108010024636 Glutathione Proteins 0.000 description 2
• 102000006587 Glutathione peroxidase Human genes 0.000 description 2
• 108700016172 Glutathione peroxidases Proteins 0.000 description 2
• 101710101434 Glutathione synthetase Proteins 0.000 description 2
• 102100034294 Glutathione synthetase Human genes 0.000 description 2
• 101710087514 Glutathione synthetase, chloroplastic Proteins 0.000 description 2
• AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
• 208000016621 Hearing disease Diseases 0.000 description 2
• 208000028782 Hereditary disease Diseases 0.000 description 2
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
• 206010020751 Hypersensitivity Diseases 0.000 description 2
• 102000004877 Insulin Human genes 0.000 description 2
• 108090001061 Insulin Proteins 0.000 description 2
• 208000009564 MELAS Syndrome Diseases 0.000 description 2
• 208000024556 Mendelian disease Diseases 0.000 description 2
• 241001465754 Metazoa Species 0.000 description 2
• 102000036675 Myoglobin Human genes 0.000 description 2
• 108010062374 Myoglobin Proteins 0.000 description 2
• 208000012902 Nervous system disease Diseases 0.000 description 2
• 206010034620 Peripheral sensory neuropathy Diseases 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
• LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
• BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
• 229920002472 Starch Polymers 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
• 206010047700 Vomiting Diseases 0.000 description 2
• 150000007513 acids Chemical class 0.000 description 2
• 239000004480 active ingredient Substances 0.000 description 2
• 239000000654 additive Substances 0.000 description 2
• 150000007514 bases Chemical class 0.000 description 2
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
• 238000011325 biochemical measurement Methods 0.000 description 2
• 230000003851 biochemical process Effects 0.000 description 2
• 210000001124 body fluid Anatomy 0.000 description 2
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
• BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 2
• 229910052799 carbon Inorganic materials 0.000 description 2
• 239000000969 carrier Substances 0.000 description 2
• 230000015556 catabolic process Effects 0.000 description 2
• 210000003850 cellular structure Anatomy 0.000 description 2
• 230000001054 cortical effect Effects 0.000 description 2
• 125000004122 cyclic group Chemical group 0.000 description 2
• 230000007547 defect Effects 0.000 description 2
• 230000007850 degeneration Effects 0.000 description 2
• 230000001419 dependent effect Effects 0.000 description 2
• 238000013461 design Methods 0.000 description 2
• 206010012601 diabetes mellitus Diseases 0.000 description 2
• 230000037213 diet Effects 0.000 description 2
• 230000000378 dietary effect Effects 0.000 description 2
• 239000003085 diluting agent Substances 0.000 description 2
• XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
• 238000012377 drug delivery Methods 0.000 description 2
• 208000010118 dystonia Diseases 0.000 description 2
• 201000009028 early myoclonic encephalopathy Diseases 0.000 description 2
• 239000003995 emulsifying agent Substances 0.000 description 2
• 206010015037 epilepsy Diseases 0.000 description 2
• 150000002148 esters Chemical class 0.000 description 2
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
• 210000003527 eukaryotic cell Anatomy 0.000 description 2
• 238000011156 evaluation Methods 0.000 description 2
• 230000029142 excretion Effects 0.000 description 2
• 238000000605 extraction Methods 0.000 description 2
• 239000012894 fetal calf serum Substances 0.000 description 2
• 235000019162 flavin adenine dinucleotide Nutrition 0.000 description 2
• 239000011714 flavin adenine dinucleotide Substances 0.000 description 2
• 230000004907 flux Effects 0.000 description 2
• 230000006870 function Effects 0.000 description 2
• 239000011521 glass Substances 0.000 description 2
• 239000008103 glucose Substances 0.000 description 2
• 239000008187 granular material Substances 0.000 description 2
• 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
• 239000003112 inhibitor Substances 0.000 description 2
• 230000005764 inhibitory process Effects 0.000 description 2
• 229910052500 inorganic mineral Inorganic materials 0.000 description 2
• 229940125396 insulin Drugs 0.000 description 2
• 238000007918 intramuscular administration Methods 0.000 description 2
• 238000001990 intravenous administration Methods 0.000 description 2
• 230000033001 locomotion Effects 0.000 description 2
• 235000019359 magnesium stearate Nutrition 0.000 description 2
• 230000001404 mediated effect Effects 0.000 description 2
• 230000004060 metabolic process Effects 0.000 description 2
• BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
• 239000011707 mineral Substances 0.000 description 2
• 235000010755 mineral Nutrition 0.000 description 2
• 230000008811 mitochondrial respiratory chain Effects 0.000 description 2
• 201000001119 neuropathy Diseases 0.000 description 2
• 230000007823 neuropathy Effects 0.000 description 2
• 230000007935 neutral effect Effects 0.000 description 2
• 239000000346 nonvolatile oil Substances 0.000 description 2
• 206010029864 nystagmus Diseases 0.000 description 2
• 239000003921 oil Substances 0.000 description 2
• 235000019198 oils Nutrition 0.000 description 2
• 108010007425 oligomycin sensitivity conferring protein Proteins 0.000 description 2
• 208000001749 optic atrophy Diseases 0.000 description 2
• 239000003960 organic solvent Substances 0.000 description 2
• 230000037361 pathway Effects 0.000 description 2
• 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
• 230000002093 peripheral effect Effects 0.000 description 2
• 208000033808 peripheral neuropathy Diseases 0.000 description 2
• 239000002953 phosphate buffered saline Substances 0.000 description 2
• 150000003904 phospholipids Chemical class 0.000 description 2
• 239000011772 phylloquinone Substances 0.000 description 2
• 230000000704 physical effect Effects 0.000 description 2
• 239000003755 preservative agent Substances 0.000 description 2
• YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
• 229910052711 selenium Inorganic materials 0.000 description 2
• 239000011669 selenium Substances 0.000 description 2
• 201000005572 sensory peripheral neuropathy Diseases 0.000 description 2
• 150000003384 small molecules Chemical class 0.000 description 2
• 239000007787 solid Substances 0.000 description 2
• 239000007909 solid dosage form Substances 0.000 description 2
• 239000003381 stabilizer Substances 0.000 description 2
• 239000008107 starch Substances 0.000 description 2
• 235000019698 starch Nutrition 0.000 description 2
• 239000011550 stock solution Substances 0.000 description 2
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
• 239000013589 supplement Substances 0.000 description 2
• 239000000829 suppository Substances 0.000 description 2
• 229960000984 tocofersolan Drugs 0.000 description 2
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
• 210000002700 urine Anatomy 0.000 description 2
• 230000008673 vomiting Effects 0.000 description 2
• 239000000080 wetting agent Substances 0.000 description 2
• QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
• LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
• WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
• GJJVAFUKOBZPCB-ZGRPYONQSA-N (r)-3,4-dihydro-2-methyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2h-1-benzopyran-6-ol Chemical class OC1=CC=C2OC(CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-ZGRPYONQSA-N 0.000 description 1
• WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
• UHIVVFCEUPYRSW-UHFFFAOYSA-N 2,6,7-trimethyl-3-(3,7,11-trimethyldodeca-2,6,10-trienyl)naphthalene-1,4-dione Chemical compound CC1=C(C)C=C2C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C(=O)C2=C1 UHIVVFCEUPYRSW-UHFFFAOYSA-N 0.000 description 1
• MZGNQWZTJHWPRJ-UHFFFAOYSA-N 2,6,7-trimethyl-3-(3,7,11-trimethyldodecyl)naphthalene-1,4-dione Chemical compound CC1=C(C)C=C2C(=O)C(CCC(C)CCCC(C)CCCC(C)C)=C(C)C(=O)C2=C1 MZGNQWZTJHWPRJ-UHFFFAOYSA-N 0.000 description 1
• GMLZGGUFMPVELH-UHFFFAOYSA-N 2,6,7-trimethyl-3-(3-methylbutyl)naphthalene-1,4-dione Chemical compound CC1=C(C)C=C2C(=O)C(CCC(C)C)=C(C)C(=O)C2=C1 GMLZGGUFMPVELH-UHFFFAOYSA-N 0.000 description 1
• BPQDCHVEYHNHLJ-UHFFFAOYSA-N 2,6,7-trimethyl-3-nonylnaphthalene-1,4-dione Chemical compound CC1=C(C)C=C2C(=O)C(CCCCCCCCC)=C(C)C(=O)C2=C1 BPQDCHVEYHNHLJ-UHFFFAOYSA-N 0.000 description 1
• RMVJPPRVWLGUHW-UHFFFAOYSA-N 2,6,7-trimethyl-3-octylnaphthalene-1,4-dione Chemical compound CC1=C(C)C=C2C(=O)C(CCCCCCCC)=C(C)C(=O)C2=C1 RMVJPPRVWLGUHW-UHFFFAOYSA-N 0.000 description 1
• CHLABMNNTMQLEX-UHFFFAOYSA-N 2,6,7-trimethyl-3-pentylnaphthalene-1,4-dione Chemical compound CC1=C(C)C=C2C(=O)C(CCCCC)=C(C)C(=O)C2=C1 CHLABMNNTMQLEX-UHFFFAOYSA-N 0.000 description 1
• JLZNXWIULXFKNI-UHFFFAOYSA-N 2,6,7-trimethyl-3-propylnaphthalene-1,4-dione Chemical compound CC1=C(C)C=C2C(=O)C(CCC)=C(C)C(=O)C2=C1 JLZNXWIULXFKNI-UHFFFAOYSA-N 0.000 description 1
• MSRIJIIRLUFUML-UHFFFAOYSA-N 2,6,7-trimethyl-3-undecylnaphthalene-1,4-dione Chemical compound CC1=C(C)C=C2C(=O)C(CCCCCCCCCCC)=C(C)C(=O)C2=C1 MSRIJIIRLUFUML-UHFFFAOYSA-N 0.000 description 1
• GWUPSSOOTJSELT-UHFFFAOYSA-N 2,6-dimethyl-3-undecylnaphthalene-1,4-dione Chemical compound C1=C(C)C=C2C(=O)C(CCCCCCCCCCC)=C(C)C(=O)C2=C1 GWUPSSOOTJSELT-UHFFFAOYSA-N 0.000 description 1
• UNUQVCXDSADTSK-UHFFFAOYSA-N 2-(3,7-dimethyloct-2-enyl)-3,6,7-trimethylnaphthalene-1,4-dione Chemical compound CC1=C(C)C=C2C(=O)C(CC=C(C)CCCC(C)C)=C(C)C(=O)C2=C1 UNUQVCXDSADTSK-UHFFFAOYSA-N 0.000 description 1
• CTMGTOSGYIEFON-UHFFFAOYSA-N 2-(3,7-dimethyloct-2-enyl)-6,7-dimethoxy-3-methylnaphthalene-1,4-dione Chemical compound O=C1C(C)=C(CC=C(C)CCCC(C)C)C(=O)C2=C1C=C(OC)C(OC)=C2 CTMGTOSGYIEFON-UHFFFAOYSA-N 0.000 description 1
• ORSMHGTWYRCYIH-UHFFFAOYSA-N 2-(3,7-dimethylocta-2,6-dienyl)-3,6,7-trimethylnaphthalene-1,4-dione Chemical compound CC1=C(C)C=C2C(=O)C(CC=C(C)CCC=C(C)C)=C(C)C(=O)C2=C1 ORSMHGTWYRCYIH-UHFFFAOYSA-N 0.000 description 1
• HNAJMQDWVMKIHT-UHFFFAOYSA-N 2-(3,7-dimethylocta-2,6-dienyl)-6,7-dimethoxy-3-methylnaphthalene-1,4-dione Chemical compound O=C1C(C)=C(CC=C(C)CCC=C(C)C)C(=O)C2=C1C=C(OC)C(OC)=C2 HNAJMQDWVMKIHT-UHFFFAOYSA-N 0.000 description 1
• CPXZIJKXPKCXEO-UHFFFAOYSA-N 2-(3,7-dimethyloctyl)-3,6,7-trimethylnaphthalene-1,4-dione Chemical compound CC1=C(C)C=C2C(=O)C(CCC(C)CCCC(C)C)=C(C)C(=O)C2=C1 CPXZIJKXPKCXEO-UHFFFAOYSA-N 0.000 description 1
• UYJFRDNZDJMUGZ-UHFFFAOYSA-N 2-(3,7-dimethyloctyl)-3-methylnaphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(CCC(C)CCCC(C)C)=C(C)C(=O)C2=C1 UYJFRDNZDJMUGZ-UHFFFAOYSA-N 0.000 description 1
• NYOCEMKOYRVRHG-UHFFFAOYSA-N 2-(3,7-dimethyloctyl)-6,7-dimethoxy-3-methylnaphthalene-1,4-dione Chemical compound O=C1C(C)=C(CCC(C)CCCC(C)C)C(=O)C2=C1C=C(OC)C(OC)=C2 NYOCEMKOYRVRHG-UHFFFAOYSA-N 0.000 description 1
• ZYZWUEIPVNFQQC-UHFFFAOYSA-N 2-(3-hydroxy-3,7,11,15-tetramethylhexadecyl)-3-methylnaphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(CCC(C)(O)CCCC(C)CCCC(C)CCCC(C)C)=C(C)C(=O)C2=C1 ZYZWUEIPVNFQQC-UHFFFAOYSA-N 0.000 description 1
• KWRKLFIAEYPQKN-UHFFFAOYSA-N 2-(3-hydroxy-3,7-dimethyloct-6-enyl)-3,6,7-trimethylnaphthalene-1,4-dione Chemical compound CC1=C(C)C=C2C(=O)C(CCC(C)(O)CCC=C(C)C)=C(C)C(=O)C2=C1 KWRKLFIAEYPQKN-UHFFFAOYSA-N 0.000 description 1
• DTTWBQYWQSTJBG-UHFFFAOYSA-N 2-(3-hydroxy-3,7-dimethyloct-6-enyl)-6,7-dimethoxy-3-methylnaphthalene-1,4-dione Chemical compound O=C1C(C)=C(CCC(C)(O)CCC=C(C)C)C(=O)C2=C1C=C(OC)C(OC)=C2 DTTWBQYWQSTJBG-UHFFFAOYSA-N 0.000 description 1
• UEMUUGYGCYGFMV-UHFFFAOYSA-N 2-(3-hydroxy-3,7-dimethyloct-6-enyl)-6,7-dimethylnaphthalene-1,4-dione Chemical compound CC1=C(C)C=C2C(=O)C(CCC(C)(O)CCC=C(C)C)=CC(=O)C2=C1 UEMUUGYGCYGFMV-UHFFFAOYSA-N 0.000 description 1
• PFCSRGNFXBREEI-UHFFFAOYSA-N 2-(3-hydroxy-3,7-dimethyloct-6-enyl)naphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(CCC(C)(O)CCC=C(C)C)=CC(=O)C2=C1 PFCSRGNFXBREEI-UHFFFAOYSA-N 0.000 description 1
• GDHNCWLXFAGPQX-UHFFFAOYSA-N 2-(3-hydroxy-3,7-dimethyloctyl)-3,6,7-trimethylnaphthalene-1,4-dione Chemical compound CC1=C(C)C=C2C(=O)C(CCC(C)(O)CCCC(C)C)=C(C)C(=O)C2=C1 GDHNCWLXFAGPQX-UHFFFAOYSA-N 0.000 description 1
• UGUBRMHJQSMRMJ-UHFFFAOYSA-N 2-(3-hydroxy-3,7-dimethyloctyl)-6,7-dimethylnaphthalene-1,4-dione Chemical compound CC1=C(C)C=C2C(=O)C(CCC(C)(O)CCCC(C)C)=CC(=O)C2=C1 UGUBRMHJQSMRMJ-UHFFFAOYSA-N 0.000 description 1
• CNGWXCGJMYIOSR-UHFFFAOYSA-N 2-(3-hydroxy-3,7-dimethyloctyl)naphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(CCC(C)(O)CCCC(C)C)=CC(=O)C2=C1 CNGWXCGJMYIOSR-UHFFFAOYSA-N 0.000 description 1
• PFRQBZFETXBLTP-RCIYGOBDSA-N 2-[(2e,6e,10e,14e,18e)-3,7,11,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaen-1-yl]-3-methyl-1,4-dihydronaphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 PFRQBZFETXBLTP-RCIYGOBDSA-N 0.000 description 1
• OCQQATZYCNAKQB-UQUNHUMXSA-N 2-[(2e,6e,10e,14e,18e,22e,26e,30e,34e)-3,7,11,15,19,23,27,31,35,39-decamethyltetraconta-2,6,10,14,18,22,26,30,34,38-decaenyl]-3-methylnaphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 OCQQATZYCNAKQB-UQUNHUMXSA-N 0.000 description 1
• SMVFMAYRSAMHNF-UHFFFAOYSA-N 2-butyl-3,6,7-trimethylnaphthalene-1,4-dione Chemical compound CC1=C(C)C=C2C(=O)C(CCCC)=C(C)C(=O)C2=C1 SMVFMAYRSAMHNF-UHFFFAOYSA-N 0.000 description 1
• KTAFHXYETWATCI-UHFFFAOYSA-N 2-butyl-6,7-dimethoxy-3-methylnaphthalene-1,4-dione Chemical compound COC1=C(OC)C=C2C(=O)C(CCCC)=C(C)C(=O)C2=C1 KTAFHXYETWATCI-UHFFFAOYSA-N 0.000 description 1
• UKIISDIRWKMOLU-UHFFFAOYSA-N 2-decyl-3,6,7-trimethylnaphthalene-1,4-dione Chemical compound CC1=C(C)C=C2C(=O)C(CCCCCCCCCC)=C(C)C(=O)C2=C1 UKIISDIRWKMOLU-UHFFFAOYSA-N 0.000 description 1
• SVPFQLOQDFPLGP-UHFFFAOYSA-N 2-decyl-6,7-dimethoxy-3-methylnaphthalene-1,4-dione Chemical compound COC1=C(OC)C=C2C(=O)C(CCCCCCCCCC)=C(C)C(=O)C2=C1 SVPFQLOQDFPLGP-UHFFFAOYSA-N 0.000 description 1
• UOTFOTKILFDVRN-UHFFFAOYSA-N 2-ethyl-3,6,7-trimethylnaphthalene-1,4-dione Chemical compound CC1=C(C)C=C2C(=O)C(CC)=C(C)C(=O)C2=C1 UOTFOTKILFDVRN-UHFFFAOYSA-N 0.000 description 1
• RXIPJLKIAUIJNY-UHFFFAOYSA-N 2-ethyl-6,7-dimethoxy-3-methylnaphthalene-1,4-dione Chemical compound COC1=C(OC)C=C2C(=O)C(CC)=C(C)C(=O)C2=C1 RXIPJLKIAUIJNY-UHFFFAOYSA-N 0.000 description 1
• DTGKPFYIFROSOP-UHFFFAOYSA-N 2-heptadecyl-3-methylnaphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(CCCCCCCCCCCCCCCCC)=C(C)C(=O)C2=C1 DTGKPFYIFROSOP-UHFFFAOYSA-N 0.000 description 1
• FSCUHUWRVXNOSP-UHFFFAOYSA-N 2-heptyl-3,6,7-trimethylnaphthalene-1,4-dione Chemical compound CC1=C(C)C=C2C(=O)C(CCCCCCC)=C(C)C(=O)C2=C1 FSCUHUWRVXNOSP-UHFFFAOYSA-N 0.000 description 1
• YAKBITAXCOOTRG-UHFFFAOYSA-N 2-heptyl-3-methylnaphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(CCCCCCC)=C(C)C(=O)C2=C1 YAKBITAXCOOTRG-UHFFFAOYSA-N 0.000 description 1
• CUZJODGMMCHUGB-UHFFFAOYSA-N 2-heptyl-6,7-dimethoxy-3-methylnaphthalene-1,4-dione Chemical compound COC1=C(OC)C=C2C(=O)C(CCCCCCC)=C(C)C(=O)C2=C1 CUZJODGMMCHUGB-UHFFFAOYSA-N 0.000 description 1
• BJUQOCBGPDMWJT-UHFFFAOYSA-N 2-hexyl-3,6,7-trimethylnaphthalene-1,4-dione Chemical compound CC1=C(C)C=C2C(=O)C(CCCCCC)=C(C)C(=O)C2=C1 BJUQOCBGPDMWJT-UHFFFAOYSA-N 0.000 description 1
• QEVQGOUIQMNQBA-UHFFFAOYSA-N 2-hexyl-6,7-dimethoxy-3-methylnaphthalene-1,4-dione Chemical compound COC1=C(OC)C=C2C(=O)C(CCCCCC)=C(C)C(=O)C2=C1 QEVQGOUIQMNQBA-UHFFFAOYSA-N 0.000 description 1
• FATIXBDICXNSAQ-UHFFFAOYSA-N 2-icosyl-3-methylnaphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(CCCCCCCCCCCCCCCCCCCC)=C(C)C(=O)C2=C1 FATIXBDICXNSAQ-UHFFFAOYSA-N 0.000 description 1
• MOYPRYFRIDZWHC-UHFFFAOYSA-N 2-methyl-3-(3,7,11-trimethyldodecyl)naphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(CCC(C)CCCC(C)CCCC(C)C)=C(C)C(=O)C2=C1 MOYPRYFRIDZWHC-UHFFFAOYSA-N 0.000 description 1
• JCSUQQOAHQRPBF-UHFFFAOYSA-N 2-methyl-3-(3-methylbutyl)naphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(CCC(C)C)=C(C)C(=O)C2=C1 JCSUQQOAHQRPBF-UHFFFAOYSA-N 0.000 description 1
• HYPYXGZDOYTYDR-HAJWAVTHSA-N 2-methyl-3-[(2e,6e,10e,14e)-3,7,11,15,19-pentamethylicosa-2,6,10,14,18-pentaenyl]naphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 HYPYXGZDOYTYDR-HAJWAVTHSA-N 0.000 description 1
• YYDMANIEKFAEJC-RYZSZPJESA-N 2-methyl-3-[(2e,6e,10e,14e,18e,22e,26e,30e,34e,38e)-3,7,11,15,19,23,27,31,35,39,43-undecamethyltetratetraconta-2,6,10,14,18,22,26,30,34,38,42-undecaenyl]naphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 YYDMANIEKFAEJC-RYZSZPJESA-N 0.000 description 1
• SUVLFHKXBHCAKS-UHFFFAOYSA-N 2-methyl-3-nonadecylnaphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(CCCCCCCCCCCCCCCCCCC)=C(C)C(=O)C2=C1 SUVLFHKXBHCAKS-UHFFFAOYSA-N 0.000 description 1
• ANJYWYTXJPIQLS-UHFFFAOYSA-N 2-methyl-3-octylnaphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(CCCCCCCC)=C(C)C(=O)C2=C1 ANJYWYTXJPIQLS-UHFFFAOYSA-N 0.000 description 1
• ONKIICPFVVQPJA-UHFFFAOYSA-N 2-methyl-3-pentadecylnaphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(CCCCCCCCCCCCCCC)=C(C)C(=O)C2=C1 ONKIICPFVVQPJA-UHFFFAOYSA-N 0.000 description 1
• XTMWDFCOWHNAPA-UHFFFAOYSA-N 2-methyl-3-pentylnaphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(CCCCC)=C(C)C(=O)C2=C1 XTMWDFCOWHNAPA-UHFFFAOYSA-N 0.000 description 1
• PUURYLDVOHSJSZ-UHFFFAOYSA-N 2-methyl-3-tetradecylnaphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(CCCCCCCCCCCCCC)=C(C)C(=O)C2=C1 PUURYLDVOHSJSZ-UHFFFAOYSA-N 0.000 description 1
• MVFUHAWRIKCIAB-UHFFFAOYSA-N 2-methyl-3-tridecylnaphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(CCCCCCCCCCCCC)=C(C)C(=O)C2=C1 MVFUHAWRIKCIAB-UHFFFAOYSA-N 0.000 description 1
• LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
• QIKRGFPWBPVTQR-UHFFFAOYSA-N 3,6-dimethyl-2-undecylnaphthalene-1,4-dione Chemical compound CC1=CC=C2C(=O)C(CCCCCCCCCCC)=C(C)C(=O)C2=C1 QIKRGFPWBPVTQR-UHFFFAOYSA-N 0.000 description 1
• BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
• OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
• HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
• VRXKLGCNYCPUJH-UHFFFAOYSA-N 6,7-dimethoxy-2-methyl-3-(3,7,11-trimethyldodeca-2,6,10-trienyl)naphthalene-1,4-dione Chemical compound COc1cc2C(=O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)C)C(=O)c2cc1OC VRXKLGCNYCPUJH-UHFFFAOYSA-N 0.000 description 1
• MGTPSHSMGWFPLY-UHFFFAOYSA-N 6,7-dimethoxy-2-methyl-3-(3,7,11-trimethyldodecyl)naphthalene-1,4-dione Chemical compound O=C1C(C)=C(CCC(C)CCCC(C)CCCC(C)C)C(=O)C2=C1C=C(OC)C(OC)=C2 MGTPSHSMGWFPLY-UHFFFAOYSA-N 0.000 description 1
• FNRUPLSTOFMRIV-UHFFFAOYSA-N 6,7-dimethoxy-2-methyl-3-(3-methylbutyl)naphthalene-1,4-dione Chemical compound O=C1C(C)=C(CCC(C)C)C(=O)C2=C1C=C(OC)C(OC)=C2 FNRUPLSTOFMRIV-UHFFFAOYSA-N 0.000 description 1
• WSTYZSMLJKKMJD-UHFFFAOYSA-N 6,7-dimethoxy-2-methyl-3-nonylnaphthalene-1,4-dione Chemical compound COC1=C(OC)C=C2C(=O)C(CCCCCCCCC)=C(C)C(=O)C2=C1 WSTYZSMLJKKMJD-UHFFFAOYSA-N 0.000 description 1
• PBUGHKYUPAWDHL-UHFFFAOYSA-N 6,7-dimethoxy-2-methyl-3-octylnaphthalene-1,4-dione Chemical compound COC1=C(OC)C=C2C(=O)C(CCCCCCCC)=C(C)C(=O)C2=C1 PBUGHKYUPAWDHL-UHFFFAOYSA-N 0.000 description 1
• HUZYCJQOJZHFOC-UHFFFAOYSA-N 6,7-dimethoxy-2-methyl-3-pentylnaphthalene-1,4-dione Chemical compound COC1=C(OC)C=C2C(=O)C(CCCCC)=C(C)C(=O)C2=C1 HUZYCJQOJZHFOC-UHFFFAOYSA-N 0.000 description 1
• MUTDRCKRAWDAEI-UHFFFAOYSA-N 6,7-dimethoxy-2-methyl-3-propylnaphthalene-1,4-dione Chemical compound COC1=C(OC)C=C2C(=O)C(CCC)=C(C)C(=O)C2=C1 MUTDRCKRAWDAEI-UHFFFAOYSA-N 0.000 description 1
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
• QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
• 206010069754 Acquired gene mutation Diseases 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• 241001550224 Apha Species 0.000 description 1
• 239000005711 Benzoic acid Substances 0.000 description 1
• 208000020925 Bipolar disease Diseases 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
• FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
• WVIIJEIPOUIGNY-UHFFFAOYSA-N COC=1C(C2=CC=CC=C2C(C1)=O)=O.COC=1C(C2=CC=CC=C2C(C1OC)=O)=O Chemical compound COC=1C(C2=CC=CC=C2C(C1)=O)=O.COC=1C(C2=CC=CC=C2C(C1OC)=O)=O WVIIJEIPOUIGNY-UHFFFAOYSA-N 0.000 description 1
• 101100007300 Caenorhabditis elegans coq-2 gene Proteins 0.000 description 1
• 208000002061 Cardiac Conduction System Disease Diseases 0.000 description 1
• 208000002177 Cataract Diseases 0.000 description 1
• 206010008027 Cerebellar atrophy Diseases 0.000 description 1
• WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
• 206010010071 Coma Diseases 0.000 description 1
• 208000027205 Congenital disease Diseases 0.000 description 1
• 208000029767 Congenital, Hereditary, and Neonatal Diseases and Abnormalities Diseases 0.000 description 1
• 206010011469 Crying Diseases 0.000 description 1
• 102100029079 Cytochrome c oxidase assembly protein COX15 homolog Human genes 0.000 description 1
• 102100028203 Cytochrome c oxidase subunit 3 Human genes 0.000 description 1
• 230000005778 DNA damage Effects 0.000 description 1
• 231100000277 DNA damage Toxicity 0.000 description 1
• 206010011953 Decreased activity Diseases 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
• 206010013887 Dysarthria Diseases 0.000 description 1
• 208000000059 Dyspnea Diseases 0.000 description 1
• 206010013975 Dyspnoeas Diseases 0.000 description 1
• LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
• 241000792859 Enema Species 0.000 description 1
• 101800003838 Epidermal growth factor Proteins 0.000 description 1
• 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
• 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
• 102000003869 Frataxin Human genes 0.000 description 1
• 108090000217 Frataxin Proteins 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 206010019280 Heart failures Diseases 0.000 description 1
• 101000770637 Homo sapiens Cytochrome c oxidase assembly protein COX15 homolog Proteins 0.000 description 1
• 101000861034 Homo sapiens Cytochrome c oxidase subunit 3 Proteins 0.000 description 1
• 101000874364 Homo sapiens Protein SCO2 homolog, mitochondrial Proteins 0.000 description 1
• 101000919980 Homo sapiens Protoheme IX farnesyltransferase, mitochondrial Proteins 0.000 description 1
• 208000000038 Hypoparathyroidism Diseases 0.000 description 1
• 238000004566 IR spectroscopy Methods 0.000 description 1
• 208000026350 Inborn Genetic disease Diseases 0.000 description 1
• 206010022998 Irritability Diseases 0.000 description 1
• 208000032382 Ischaemic stroke Diseases 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical class OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 206010024264 Lethargy Diseases 0.000 description 1
• 241000124008 Mammalia Species 0.000 description 1
• ABSPRNADVQNDOU-UHFFFAOYSA-N Menaquinone 1 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(C)C(=O)C2=C1 ABSPRNADVQNDOU-UHFFFAOYSA-N 0.000 description 1
• 208000036626 Mental retardation Diseases 0.000 description 1
• 108020005196 Mitochondrial DNA Proteins 0.000 description 1
• 206010052641 Mitochondrial DNA mutation Diseases 0.000 description 1
• 208000019022 Mood disease Diseases 0.000 description 1
• 108010085220 Multiprotein Complexes Proteins 0.000 description 1
• 102000007474 Multiprotein Complexes Human genes 0.000 description 1
• 208000007101 Muscle Cramp Diseases 0.000 description 1
• 208000010428 Muscle Weakness Diseases 0.000 description 1
• 206010028372 Muscular weakness Diseases 0.000 description 1
• 206010069825 Myoclonic epilepsy and ragged-red fibres Diseases 0.000 description 1
• 208000002033 Myoclonus Diseases 0.000 description 1
• 206010028629 Myoglobinuria Diseases 0.000 description 1
• HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
• 102000006746 NADH Dehydrogenase Human genes 0.000 description 1
• 108010086428 NADH Dehydrogenase Proteins 0.000 description 1
• 206010029164 Nephrotic syndrome Diseases 0.000 description 1
• 208000025966 Neurological disease Diseases 0.000 description 1
• GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
• 239000005642 Oleic acid Substances 0.000 description 1
• ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
• 102000004316 Oxidoreductases Human genes 0.000 description 1
• 108090000854 Oxidoreductases Proteins 0.000 description 1
• 229930182555 Penicillin Natural products 0.000 description 1
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
• 102000035195 Peptidases Human genes 0.000 description 1
• 108091005804 Peptidases Proteins 0.000 description 1
• BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
• 239000004952 Polyamide Substances 0.000 description 1
• 229920002732 Polyanhydride Polymers 0.000 description 1
• 229920001710 Polyorthoester Polymers 0.000 description 1
• 206010036437 Posturing Diseases 0.000 description 1
• 239000004365 Protease Substances 0.000 description 1
• 102100035546 Protein SCO2 homolog, mitochondrial Human genes 0.000 description 1
• 102100030729 Protoheme IX farnesyltransferase, mitochondrial Human genes 0.000 description 1
• IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
• WHBMMWSBFZVSSR-UHFFFAOYSA-N R3HBA Natural products CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 1
• 208000001647 Renal Insufficiency Diseases 0.000 description 1
• 241000219061 Rheum Species 0.000 description 1
• 235000019485 Safflower oil Nutrition 0.000 description 1
• 208000032023 Signs and Symptoms Diseases 0.000 description 1
• 208000005392 Spasm Diseases 0.000 description 1
• 102000019259 Succinate Dehydrogenase Human genes 0.000 description 1
• 108010012901 Succinate Dehydrogenase Proteins 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
• 206010047634 Vitamin K deficiency Diseases 0.000 description 1
• PFRQBZFETXBLTP-UHFFFAOYSA-N Vitamin K2 Natural products C1=CC=C2C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C(=O)C2=C1 PFRQBZFETXBLTP-UHFFFAOYSA-N 0.000 description 1
• 208000027418 Wounds and injury Diseases 0.000 description 1
• 235000011054 acetic acid Nutrition 0.000 description 1
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 239000008186 active pharmaceutical agent Substances 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 150000001298 alcohols Chemical class 0.000 description 1
• 125000001931 aliphatic group Chemical group 0.000 description 1
• 229910052783 alkali metal Inorganic materials 0.000 description 1
• 150000001340 alkali metals Chemical class 0.000 description 1
• MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 1
• 229940087168 alpha tocopherol Drugs 0.000 description 1
• AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
• 150000003863 ammonium salts Chemical class 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 230000004596 appetite loss Effects 0.000 description 1
• 238000013459 approach Methods 0.000 description 1
• 239000012736 aqueous medium Substances 0.000 description 1
• 206010003246 arthritis Diseases 0.000 description 1
• 239000012298 atmosphere Substances 0.000 description 1
• JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
• 235000010233 benzoic acid Nutrition 0.000 description 1
• 235000013361 beverage Nutrition 0.000 description 1
• 230000002146 bilateral effect Effects 0.000 description 1
• 238000010256 biochemical assay Methods 0.000 description 1
• 230000008238 biochemical pathway Effects 0.000 description 1
• 238000010876 biochemical test Methods 0.000 description 1
• 230000004071 biological effect Effects 0.000 description 1
• 230000031018 biological processes and functions Effects 0.000 description 1
• 239000012472 biological sample Substances 0.000 description 1
• 229960000074 biopharmaceutical Drugs 0.000 description 1
• 230000017531 blood circulation Effects 0.000 description 1
• 239000010839 body fluid Substances 0.000 description 1
• 230000036760 body temperature Effects 0.000 description 1
• 239000006172 buffering agent Substances 0.000 description 1
• KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 229910000389 calcium phosphate Inorganic materials 0.000 description 1
• 235000011010 calcium phosphates Nutrition 0.000 description 1
• 159000000007 calcium salts Chemical class 0.000 description 1
• 229910002091 carbon monoxide Inorganic materials 0.000 description 1
• 239000001768 carboxy methyl cellulose Substances 0.000 description 1
• 239000012876 carrier material Substances 0.000 description 1
• 239000006143 cell culture medium Substances 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 235000010980 cellulose Nutrition 0.000 description 1
• 235000013339 cereals Nutrition 0.000 description 1
• 210000004289 cerebral ventricle Anatomy 0.000 description 1
• 238000006243 chemical reaction Methods 0.000 description 1
• 239000003153 chemical reaction reagent Substances 0.000 description 1
• 235000013985 cinnamic acid Nutrition 0.000 description 1
• 229930016911 cinnamic acid Natural products 0.000 description 1
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
• 229960004316 cisplatin Drugs 0.000 description 1
• 235000015165 citric acid Nutrition 0.000 description 1
• 238000003776 cleavage reaction Methods 0.000 description 1
• 230000009194 climbing Effects 0.000 description 1
• 230000007012 clinical effect Effects 0.000 description 1
• 229940110456 cocoa butter Drugs 0.000 description 1
• 235000019868 cocoa butter Nutrition 0.000 description 1
• 239000003240 coconut oil Substances 0.000 description 1
• 235000019864 coconut oil Nutrition 0.000 description 1
• 230000000112 colonic effect Effects 0.000 description 1
• 238000004891 communication Methods 0.000 description 1
• 239000012141 concentrate Substances 0.000 description 1
• 235000008504 concentrate Nutrition 0.000 description 1
• 235000009508 confectionery Nutrition 0.000 description 1
• 239000000470 constituent Substances 0.000 description 1
• 238000013270 controlled release Methods 0.000 description 1
• 239000000599 controlled substance Substances 0.000 description 1
• 229920001577 copolymer Polymers 0.000 description 1
• 230000002596 correlated effect Effects 0.000 description 1
• 230000000875 corresponding effect Effects 0.000 description 1
• 235000012343 cottonseed oil Nutrition 0.000 description 1
• 239000002385 cottonseed oil Substances 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 229940097362 cyclodextrins Drugs 0.000 description 1
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
• 208000026615 cytochrome-c oxidase deficiency disease Diseases 0.000 description 1
• 210000000172 cytosol Anatomy 0.000 description 1
• GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
• 230000006378 damage Effects 0.000 description 1
• 230000037430 deletion Effects 0.000 description 1
• 238000012217 deletion Methods 0.000 description 1
• 238000006392 deoxygenation reaction Methods 0.000 description 1
• 230000000994 depressogenic effect Effects 0.000 description 1
• 238000001514 detection method Methods 0.000 description 1
• 230000001627 detrimental effect Effects 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• 235000014113 dietary fatty acids Nutrition 0.000 description 1
• 235000018823 dietary intake Nutrition 0.000 description 1
• 238000009792 diffusion process Methods 0.000 description 1
• 238000010790 dilution Methods 0.000 description 1
• 239000012895 dilution Substances 0.000 description 1
• 230000003292 diminished effect Effects 0.000 description 1
• 150000002016 disaccharides Chemical class 0.000 description 1
• 239000002270 dispersing agent Substances 0.000 description 1
• 239000006185 dispersion Substances 0.000 description 1
• 239000000890 drug combination Substances 0.000 description 1
• 238000009510 drug design Methods 0.000 description 1
• 238000007812 electrochemical assay Methods 0.000 description 1
• 230000001804 emulsifying effect Effects 0.000 description 1
• 230000002124 endocrine Effects 0.000 description 1
• 239000007920 enema Substances 0.000 description 1
• 229940079360 enema for constipation Drugs 0.000 description 1
• 238000005516 engineering process Methods 0.000 description 1
• 239000003623 enhancer Substances 0.000 description 1
• 239000002702 enteric coating Substances 0.000 description 1
• 238000009505 enteric coating Methods 0.000 description 1
• 229940116977 epidermal growth factor Drugs 0.000 description 1
• LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
• 229940093471 ethyl oleate Drugs 0.000 description 1
• 230000005284 excitation Effects 0.000 description 1
• 239000000284 extract Substances 0.000 description 1
• 206010016165 failure to thrive Diseases 0.000 description 1
• 239000003925 fat Substances 0.000 description 1
• 235000019197 fats Nutrition 0.000 description 1
• 229930195729 fatty acid Natural products 0.000 description 1
• 239000000194 fatty acid Substances 0.000 description 1
• 150000004665 fatty acids Chemical class 0.000 description 1
• VWWQXMAJTJZDQX-UYBVJOGSSA-N flavin adenine dinucleotide Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UYBVJOGSSA-N 0.000 description 1
• 229940093632 flavin-adenine dinucleotide Drugs 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 235000013373 food additive Nutrition 0.000 description 1
• 239000002778 food additive Substances 0.000 description 1
• 235000019253 formic acid Nutrition 0.000 description 1
• 239000001530 fumaric acid Substances 0.000 description 1
• 235000011087 fumaric acid Nutrition 0.000 description 1
• 235000013376 functional food Nutrition 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 230000002496 gastric effect Effects 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 208000016361 genetic disease Diseases 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 238000010448 genetic screening Methods 0.000 description 1
• 150000002306 glutamic acid derivatives Chemical class 0.000 description 1
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
• 150000004676 glycans Chemical class 0.000 description 1
• 150000002334 glycols Chemical class 0.000 description 1
• 230000034659 glycolysis Effects 0.000 description 1
• 230000012010 growth Effects 0.000 description 1
• 210000003128 head Anatomy 0.000 description 1
• 208000019622 heart disease Diseases 0.000 description 1
• 230000004217 heart function Effects 0.000 description 1
• 235000008216 herbs Nutrition 0.000 description 1
• 208000014188 hereditary optic neuropathy Diseases 0.000 description 1
• 235000006486 human diet Nutrition 0.000 description 1
• BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
• 239000000017 hydrogel Substances 0.000 description 1
• 230000007062 hydrolysis Effects 0.000 description 1
• 238000006460 hydrolysis reaction Methods 0.000 description 1
• 230000001660 hyperkinetic effect Effects 0.000 description 1
• 238000011065 in-situ storage Methods 0.000 description 1
• 238000011534 incubation Methods 0.000 description 1
• 108700005859 infantile histiocytoid Cardiomyopathy Proteins 0.000 description 1
• 201000010990 infantile histiocytoid cardiomyopathy Diseases 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 239000004615 ingredient Substances 0.000 description 1
• 229940102223 injectable solution Drugs 0.000 description 1
• 229940102213 injectable suspension Drugs 0.000 description 1
• 238000002347 injection Methods 0.000 description 1
• 239000007924 injection Substances 0.000 description 1
• 238000001361 intraarterial administration Methods 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 239000003456 ion exchange resin Substances 0.000 description 1
• 229920003303 ion-exchange polymer Polymers 0.000 description 1
• 230000002262 irrigation Effects 0.000 description 1
• 238000003973 irrigation Methods 0.000 description 1
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 150000002576 ketones Chemical class 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• 201000006370 kidney failure Diseases 0.000 description 1
• 230000003907 kidney function Effects 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 210000003140 lateral ventricle Anatomy 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 230000003902 lesion Effects 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 239000004973 liquid crystal related substance Substances 0.000 description 1
• 239000008297 liquid dosage form Substances 0.000 description 1
• 210000002311 liver mitochondria Anatomy 0.000 description 1
• 235000021266 loss of appetite Nutrition 0.000 description 1
• 208000019017 loss of appetite Diseases 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 159000000003 magnesium salts Chemical class 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• 239000011976 maleic acid Substances 0.000 description 1
• 238000007726 management method Methods 0.000 description 1
• 229960002510 mandelic acid Drugs 0.000 description 1
• 239000003550 marker Substances 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• DKHGMERMDICWDU-GHDNBGIDSA-N menaquinone-4 Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 DKHGMERMDICWDU-GHDNBGIDSA-N 0.000 description 1
• 239000011676 menaquinone-4 Substances 0.000 description 1
• RAKQPZMEYJZGPI-LJWNYQGCSA-N menaquinone-7 Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 RAKQPZMEYJZGPI-LJWNYQGCSA-N 0.000 description 1
• LXKDFTDVRVLXFY-WQWYCSGDSA-N menaquinone-8 Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 LXKDFTDVRVLXFY-WQWYCSGDSA-N 0.000 description 1
• WCRXHNIUHQUASO-UVZVDVBNSA-N menaquinone-9 Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 WCRXHNIUHQUASO-UVZVDVBNSA-N 0.000 description 1
• 230000037323 metabolic rate Effects 0.000 description 1
• 229920000609 methyl cellulose Polymers 0.000 description 1
• WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
• 239000001923 methylcellulose Substances 0.000 description 1
• 235000010981 methylcellulose Nutrition 0.000 description 1
• 239000003094 microcapsule Substances 0.000 description 1
• 239000011859 microparticle Substances 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 230000006667 mitochondrial pathway Effects 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 239000003607 modifier Substances 0.000 description 1
• 239000003068 molecular probe Substances 0.000 description 1
• 238000012544 monitoring process Methods 0.000 description 1
• 150000002772 monosaccharides Chemical class 0.000 description 1
• 230000004973 motor coordination Effects 0.000 description 1
• 208000005264 motor neuron disease Diseases 0.000 description 1
• 230000002151 myoclonic effect Effects 0.000 description 1
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 210000002850 nasal mucosa Anatomy 0.000 description 1
• 208000009928 nephrosis Diseases 0.000 description 1
• 231100001027 nephrosis Toxicity 0.000 description 1
• 210000005036 nerve Anatomy 0.000 description 1
• 230000001537 neural effect Effects 0.000 description 1
• 230000000626 neurodegenerative effect Effects 0.000 description 1
• 238000002610 neuroimaging Methods 0.000 description 1
• 230000000926 neurological effect Effects 0.000 description 1
• 229940101270 nicotinamide adenine dinucleotide (nad) Drugs 0.000 description 1
• 229910017604 nitric acid Inorganic materials 0.000 description 1
• 229910052757 nitrogen Inorganic materials 0.000 description 1
• 231100000344 non-irritating Toxicity 0.000 description 1
• 235000015097 nutrients Nutrition 0.000 description 1
• 235000016709 nutrition Nutrition 0.000 description 1
• ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
• 239000004006 olive oil Substances 0.000 description 1
• 235000008390 olive oil Nutrition 0.000 description 1
• 230000004768 organ dysfunction Effects 0.000 description 1
• 210000003463 organelle Anatomy 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 230000001151 other effect Effects 0.000 description 1
• 235000006408 oxalic acid Nutrition 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• 230000004783 oxidative metabolism Effects 0.000 description 1
• 210000000496 pancreas Anatomy 0.000 description 1
• FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 229940049954 penicillin Drugs 0.000 description 1
• 239000000863 peptide conjugate Substances 0.000 description 1
• 238000003359 percent control normalization Methods 0.000 description 1
• 239000002304 perfume Substances 0.000 description 1
• 239000008177 pharmaceutical agent Substances 0.000 description 1
• 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
• 150000008105 phosphatidylcholines Chemical class 0.000 description 1
• MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 description 1
• 235000019175 phylloquinone Nutrition 0.000 description 1
• 230000035479 physiological effects, processes and functions Effects 0.000 description 1
• 229960001898 phytomenadione Drugs 0.000 description 1
• 239000004033 plastic Substances 0.000 description 1
• 229920003023 plastic Polymers 0.000 description 1
• 229920002627 poly(phosphazenes) Polymers 0.000 description 1
• 229920002647 polyamide Polymers 0.000 description 1
• 229920000728 polyester Polymers 0.000 description 1
• 229920001223 polyethylene glycol Polymers 0.000 description 1
• 229920000642 polymer Polymers 0.000 description 1
• 229920001282 polysaccharide Polymers 0.000 description 1
• 239000005017 polysaccharide Substances 0.000 description 1
• 229920002635 polyurethane Polymers 0.000 description 1
• 239000004814 polyurethane Substances 0.000 description 1
• 159000000001 potassium salts Chemical class 0.000 description 1
• MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
• 229960004919 procaine Drugs 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 230000000644 propagated effect Effects 0.000 description 1
• 238000011321 prophylaxis Methods 0.000 description 1
• 235000019260 propionic acid Nutrition 0.000 description 1
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 208000025109 proximal renal tubular acidosis Diseases 0.000 description 1
• 229940107700 pyruvic acid Drugs 0.000 description 1
• IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
• 150000004053 quinones Chemical class 0.000 description 1
• 238000011084 recovery Methods 0.000 description 1
• 210000000664 rectum Anatomy 0.000 description 1
• 230000000306 recurrent effect Effects 0.000 description 1
• 230000008439 repair process Effects 0.000 description 1
• 230000004202 respiratory function Effects 0.000 description 1
• 210000001525 retina Anatomy 0.000 description 1
• 238000010079 rubber tapping Methods 0.000 description 1
• 235000005713 safflower oil Nutrition 0.000 description 1
• 239000003813 safflower oil Substances 0.000 description 1
• 229960004889 salicylic acid Drugs 0.000 description 1
• 201000000980 schizophrenia Diseases 0.000 description 1
• 230000007017 scission Effects 0.000 description 1
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 238000013207 serial dilution Methods 0.000 description 1
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
• 239000011780 sodium chloride Substances 0.000 description 1
• 159000000000 sodium salts Chemical class 0.000 description 1
• 230000037439 somatic mutation Effects 0.000 description 1
• 239000003549 soybean oil Substances 0.000 description 1
• 235000012424 soybean oil Nutrition 0.000 description 1
• 238000004611 spectroscopical analysis Methods 0.000 description 1
• 230000002269 spontaneous effect Effects 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 238000004659 sterilization and disinfection Methods 0.000 description 1
• 229960005322 streptomycin Drugs 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 238000010254 subcutaneous injection Methods 0.000 description 1
• 239000007929 subcutaneous injection Substances 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 150000005846 sugar alcohols Polymers 0.000 description 1
• 150000003460 sulfonic acids Chemical class 0.000 description 1
• 230000009469 supplementation Effects 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 229920001059 synthetic polymer Polymers 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 235000012222 talc Nutrition 0.000 description 1
• 239000011975 tartaric acid Substances 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 230000004797 therapeutic response Effects 0.000 description 1
• 239000002562 thickening agent Substances 0.000 description 1
• 230000009092 tissue dysfunction Effects 0.000 description 1
• 229930003799 tocopherol Natural products 0.000 description 1
• 235000010384 tocopherol Nutrition 0.000 description 1
• 239000011732 tocopherol Substances 0.000 description 1
• 229960001295 tocopherol Drugs 0.000 description 1
• 229930003802 tocotrienol Natural products 0.000 description 1
• 239000011731 tocotrienol Substances 0.000 description 1
• 229940068778 tocotrienols Drugs 0.000 description 1
• 235000019148 tocotrienols Nutrition 0.000 description 1
• 238000011200 topical administration Methods 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 230000009466 transformation Effects 0.000 description 1
• 230000001052 transient effect Effects 0.000 description 1
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
• 230000036325 urinary excretion Effects 0.000 description 1
• VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
• 230000000007 visual effect Effects 0.000 description 1
• 235000019143 vitamin K2 Nutrition 0.000 description 1
• 239000011728 vitamin K2 Substances 0.000 description 1
• 235000019195 vitamin supplement Nutrition 0.000 description 1
• 230000002747 voluntary effect Effects 0.000 description 1
• 239000001993 wax Substances 0.000 description 1
• 210000004885 white matter Anatomy 0.000 description 1
• 239000002076 α-tocopherol Substances 0.000 description 1
• 235000004835 α-tocopherol Nutrition 0.000 description 1